異甜菊醇衍生物NC-8之藥物動力學

巴克斯

山西大学，您好！

感谢采购，人社期刊库｜人社论文库，期间：2025/01/01~2025/12/31

感谢试用，科学期刊库｜科学论文库，期间：2024/10/20~2025/01/20

浏览高级检索

关闭
检索检索高级检索出版物检索
浏览期刊主题浏览核心期刊浏览期刊拼音浏览

关闭

查询符号(半角)	查询符号意义说明
空格	表示为「AND」两个查询词之交集
双引号 ( " " )	片语以双引号标示开始及结束，而且只寻找出现顺序相同的字词，例： " image process "
?	表示一个字母切截，输入两个?表两个字母，依此类推，例：输入「Appl?」，查得结果应为appl e , appl y … ( 常用于英文字查询 )
*	表示不限字母切截，由0~n. 例：输入「appl*」，查得结果应为appl e , appl es , appl y , appl ied , appl ication … ( 常用于英文字查询 )
AND、OR、NOT	布尔逻辑组合关键字，用来扩大或缩小查询范围的技巧。 (1) AND ：缩小查询范围 (2) OR ：扩大查询范围(3) NOT：排除不相关的范围

DOI 是数位物件识别码（ D igital O bject I dentifier ）的简称，
为物件在网路上的唯一识别码，可用于永久连结并引用目标物件。

使用DOI作为永久连结

每个DOI号前面加上「 http://dx.doi.org/ 」便成为永久网址。
如以DOI号为 10.5297/ser.1201.002 的文献为例，此文献的永久连结便是： http://dx.doi.org/ 10.5297/ser.1201.002 。
日后不论出版单位如何更动此文献位置，永久连结所指向的位置皆会即时更新，不再错失重要的研究。

引用含有DOI的文献

有DOI的文献在引用时皆应同时引用DOI。若使用APA、Chicago以外未规范DOI的引用格式，可引用DOI永久连结。

DOI可强化引用精确性、增强学术圈连结，并给予使用者跨平台的良好使用经验，目前在全世界已有超过五千万个对象申请DOI。如想对DOI的使用与概念有进一步了解，请参考（）。

书目管理工具

相关连结

问题回报

全文下载

异甜菊醇衍生物NC-8之药物动力学

Pharmacokinetics of an isosteviol derivative NC-8

巴克斯 , 博士　　导师：林淑娟　　共同指导教授：王莉萱

英文

异甜菊醇衍生物NC-8之药物动力学； Pharmacokinetics ； isosteviol-derivative ； NC-8

0 个人觉得这篇文章赞

摘要 │ 参考文献 (643) │ 国际计量

摘要〈TOP〉

并列摘要〈TOP〉

NC-8 (ent-16-oxobeyeran-19-N-methylureido) is a semi-synthetic isosteviol derivative that has shown anti-hepatitis B virus activity in Huh7 cells affecting viral DNA transcription, viral gene expression and the TLR2/NF-B signaling pathway. Thus, this study of the pharmacokinetics and metabolite identification was done as a part of development of NC-8. NC-8 was synthesized from isosteviol to get quantity sufficient for animal study, with satisfactory purity. The synthesized NC-8 is with ≥ 97 % purity. A bioanalytical method for the analysis of NC-8 in rat plasma was developed and validated. The pharmacokinetics of NC-8 was evaluated after administration at intravenous dose of 2 mg/kg, and oral doses of 2, 5 and 10 mg/kg in rats. Plasma concentrations were determined using LC-MS/MS and while urine samples from rats dosed at 10 mg/kg were scanned for metabolites using UPLC-QTOF-MS/MS. Method development and validation resulted in a lower limit of quantitation of 0.5 ng/ml. The linear scope of the standard curve was between 0.5 and 500 ng/ml (r2 = 0.9967). Both the precision (coefficient of variation; %) and accuracy (relative error; %) were within acceptable criteria of < 15 %. Recoveries ranged from 104 % to 113.4 %, and the matrix effects (absolute) were non-significant (CV ≤ 6 %). The validated method was successfully applied to investigate the pharmacokinetics of NC-8 in male Sprague-Dawley rats. The results for intravenously administered 2 mg/kg dose showed that the area under the concentration-time curve (AUC), the half-life (t1/2), steady state volume of distribution (Vss) and the systemic clearance (Cl) were 65,223.31 ± 4,269.79 ng/ml.min, 35.46 ± 7.94 min, 0.63 ± 0.032 L and 0.031 ± 0.0021 L/min, respectively. After oral administration, the pharmacokinetic parameters showed dose dependent increase. Increases in dose produced non-proportional increases in oral AUCs with values of 4,371.62 ± 3,084.81, 22,472.75 ± 9,103.33 and 135,141.83 ± 38,934.03 ng/ml.min for 2, 5 and 10 mg/kg, respectively. The clearance decreased with increase in oral dose. The bioavailability was low at approximately 1% for 2, 5 and 10 mg/kg oral doses. Oxidized and glucuronide conjugated urine metabolites of NC-8 were postulated. The method developed and validated provided an analytical means to better understand the preliminary pharmacokinetics of NC-8 for investigations on further drug development. The results showed dose-dependent pharmacokinetics of NC-8 and this could be due to saturable intestinal and hepatic first-pass effect. The metabolites excreted in urine indicate possible N-oxidation and glucuronide conjugation as part of metabolic pathways.

参考文献 ( 643 ) 〈TOP〉

1. Stevens E. The Modern Drug Discovery Process. Medicinal Chemistry: The Modern Drug Discovery Process. New York: Pearson Education, Inc.; 2014. p. 13-33.
连结：
2. Alsenz J, Kansy M. High throughput solubility measurement in drug discovery and development. Adv Drug Deliv Rev. 2007;59(7):546-67.
连结：
3. Chatelain E, Ioset JR. Drug discovery and development for neglected diseases: the DNDi model. Drug Des Devel Ther. 2011;5:175-81.
连结：
5. Anderson DC, Kodukula K. Biomarkers in pharmacology and drug discovery. Biochem Pharmacol. 2014;87(1):172-88.
连结：
6. Benjamin A, Nogueira da Costa A, Delaunois A, Rosseels ML, Valentin JP. Renal Safety Pharmacology in Drug Discovery and Development. Handbook of experimental pharmacology. 2015;229:323-52.
连结：

国际计量

〈TOP〉

E-mail ：

文章公开取用时，将寄通知信至您填写的信箱地址

E-mail ：

使用DOI作为永久连结

引用含有DOI的文献

DOI可强化引用精确性、增强学术圈连结，并给予使用者跨平台的良好使用经验，目前在全世界已有超过五千万个对象申请DOI。 如想对DOI的使用与概念有进一步了解，请参考 （ ） 。

DOI可强化引用精确性、增强学术圈连结，并给予使用者跨平台的良好使用经验，目前在全世界已有超过五千万个对象申请DOI。如想对DOI的使用与概念有进一步了解，请参考（）。